Results 1 to 10 of about 3,621 (185)
Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration [PDF]
Pharmaceutics, 2023 Milnacipran is a dual serotonin and norepinephrine reuptake inhibitor, clinically used for the treatment of major depression or fibromyalgia. Currently, there are no studies reporting the pharmacokinetics (PK) of milnacipran after intraperitoneal (IP ...
Sounak Bagchi +5 more
doaj +3 more sources
Milnacipran Has an Antihyperalgesic Effect on Cisplatin-Induced Neuropathy
Pharmaceutics, 2023 (1) Background: Milnacipran is a typical serotonin–norepinephrine reuptake inhibitor and has been shown to have analgesic effects in several pain models. However, its antihyperalgesic effect in cisplatin-induced neuropathy remains unknown.
Sun Jin Cho +6 more
doaj +2 more sources
Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system [PDF]
Frontiers in PharmacologyBackgroundMajor depressive disorder (MDD) is a global health concern, with serotonin-norepinephrine reuptake inhibitors (SNRIs) constituting a mainstay of the psychopharmacological approach to its clinical management.
Tao Huang +6 more
doaj +2 more sources
Jurnal Farmasi dan Ilmu Kefarmasian Indonesia, 2021 Background: Diabetes mellitus is a chronic disease that causes neuronal plasticity and increased hypothalamic pituitary adrenal (HPA) axis of stress disorders.
Tuhfatul Ulya +3 more
doaj +2 more sources
Brain Sciences, 2020 Milnacipran is a reuptake inhibitor of both serotonin and noradrenaline, used in the treatment of fibromyalgia with severe depression. However, few studies have been conducted on the efficacies of milnacipran drug on the functional connectivity of the ...
Seong-Ho Kim +5 more
doaj +2 more sources
Short Term Risk of Type 2 Diabetes in Patients Using Various Antidepressants Compared with Patients Using Fluoxetine [PDF]
Psychiatry and Clinical PsychopharmacologyBackground: The objective is to compare the risk of developing type 2 diabetes (T2D) within a year in patients prescribed various antidepressants (ADs) and those prescribed fluoxetine as a control group.
Hee-Cheol Kim
doaj +2 more sources
Antidepressants for pain management in adults with chronic pain: a network meta-analysis
Health Technology AssessmentBackground Chronic pain is common and costly. Antidepressants are prescribed to reduce pain. However, there has not been a network meta-analysis examining all antidepressants across all chronic pain conditions, so effectiveness and safety for most ...
Hollie Birkinshaw +9 more
doaj +2 more sources
Journal of Pharmacological Sciences, 2013 We investigated whether milnacipran, a serotonin–noradrenaline reuptake inhibitor, exhibits an antipruritic effect through the spinal action in mice.
Tsugunobu Andoh +2 more
doaj +1 more source
Неврология, нейропсихиатрия, психосоматика, 2020 Selective serotonin reuptake inhibitors (SSRI)-induced apathy syndrome occurs in 5–20% of patients taking these drugs.Objective: to investigate the possibility and advantages of switching patients with SSRI-induced apathy to treatment with a SSRI and ...
V. E. Medvedev +5 more
doaj +1 more source
Depression during the COVID-19 pandemic (analysis of clinical cases)
Неврология, нейропсихиатрия, психосоматика, 2021 Currently, in various world regions, the prevalence of depressive and anxiety disorders due to the impact of coronavirus infection is repeatedly increased compared to that in previous years.
I. Yu. Dorozhenok
doaj +1 more source